Compare Lamb Weston Holdings Inc (LW) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Natera Inc. Common Stock — how do they compare? Lamb Weston Holdings Inc trades at $53.69 (market cap $7.31B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 7.8× Lamb Weston Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 2.87% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Natera Inc. Common Stock for 0 Days on average.
| LW | NTRA | |
|---|---|---|
Market Cap | $7.31B | $57.03B |
Volume | 3,751,735 | 1,131,157 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $425.64 |
52-Week Low | $38.48 | $179.42 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $11.10B | $56.18B |
Dividend Yield | 2.87% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $51.96, up 3.55% today, showing strong momentum with four consecutive quarterly earnings beats. The stock exhibits bullish technical signals with moving averages supporting upward trends, though RSI levels suggest potential overbought conditions. Fundamentally, the company maintains solid profitability with 14.17% ROE and 3.85% net margin, while trading at reasonable valuations of 28.39 P/E and 1.09 P/S ratios. Recent dividend payments of $0.38 demonstrate shareholder returns.
LW presents a balanced investment case with analyst consensus at $53.71 offering modest upside. The company's consistent earnings outperformance and cost-saving initiatives provide support, but declining profit margins from 18.85% in 2023 to 3.84% projected for 2026 represent significant headwinds. High debt levels at $3.68 billion and ongoing legal investigations create additional risk factors that warrant careful monitoring.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
